Of the 18,000 people diagnosed with large B-cell lymphoma each year, only half will be successfully treated with chemotherapy. The 9,000 remaining patients typically have poor outcomes, with only 25% responding to additional, ...
Dec 13, 2021
0
1
Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen ...
Dec 12, 2021
0
3
Newer therapies are outpacing the current treatment for diffuse large B cell lymphoma, according to data that scientists will deliver from two major clinical trials at the American Society of Hematology (ASH) annual meeting ...
Dec 10, 2021
0
1
Research led by the University of Southampton has revealed a new fundamental feature of aggressive B-cell lymphomas which could open the door to further research into early detection and treatment of the disease.
Aug 25, 2021
0
6
Increasing knowledge about genomic biomarkers has facilitated better monitoring and personalized management of patients with B-cell malignant tumors. A new integrative, capture-based, next-generation sequencing (NGS) panel, ...
Jul 29, 2021
0
0
Cancer Research UK is collaborating with Aleta Biotherapeutics (Aleta) to trial a new therapy that 'reboots' a treatment for some people with blood cancer whose cancer starts to come back.
Jun 25, 2021
0
0
Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial led by researchers at the UCLA Jonsson Comprehensive Cancer Center found using a bilateral attack instead of the conventional ...
Apr 11, 2021
0
4
In people with central nervous system (CNS) lymphoma, cancerous B cells—a type of white blood cell—accumulate to form tumors in the brain or spinal cord, often in close proximity to blood vessels. This disease is quite ...
Feb 17, 2021
0
11
Cell-based gene therapy Breyanzi (lisocabtagene maraleucel) has been approved to treat adults with certain types of large B-cell lymphoma who have not responded to other systemic treatment, the U.S. Food and Drug Administration ...
Feb 9, 2021
0
0
Among patients with lymphoma admitted to the hospital for severe COVID-19, those treated with B-cell-depleting therapies within the previous 12 months had an increased risk of prolonged hospital stay and death, according ...
Feb 4, 2021
0
3
